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For decades, the rationale for treatment of gastro-oesophageal reflux disease (GORD) with 
acid suppressors, such as proton pump inhibitors (PPIs), was that symptoms were 
attributable to reflux of acidic stomach contents into the oesophagus. However, recent 
advances in the understanding of how brain-gut interactions can modulate the perception of 
visceral stimuli have complicated the concept of GORD.1 It is increasingly evident that 
altered perception of reflux is an important underlying cause of symptoms.2 A number of 
syndromes related to visceral hypersensitivity and central nervous system dysregulation are 
now recognized as “functional” gastrointestinal (GI) disorders, potentially localised to the 
oesophagus,3 bowel, stomach, duodenum, anorectum, gallbladder, or multiple GI sites in the 
same patient. These functional syndromes are common; an internet-based health survey of 
almost 6,000 adults in the US, Canada, and the UK found that 35% had symptoms 
compatible with some functional GI disorder and 7% met diagnostic criteria for a functional 
oesophageal disorder.4 This could potentially account for a large fraction of the adults with 
weekly reflux symptoms in population-based assessments (global prevalence ~13%).5 
However, it being impractical to investigate all of these patients, the recognition of altered 
perception as a major determinant of reflux symptoms has had little impact on management 
in general practice.  
To provide guidance for the management of uninvestigated reflux symptoms in primary care, 
a series of sponsored (RB Healthcare Ltd., UK) workshops were held among 
gastroenterologists, GI surgeons and general practitioners. The objective was to translate 
recent research findings into clinical practice strategies.  
Reflux symptom prevalence is increasing, but is GORD?  
Epidemiological data suggest that the prevalence of GORD has increased considerably 
since the mid 1990s. However, wider public awareness of the link between reflux symptoms 
and oesophageal cancer6 has likely contributed to the increased presentation of 
symptomatic patients in primary care. Additionally, the more we understand the multifaceted 
pathophysiology of reflux symptoms, the more it becomes clear that the Montreal Definition 
(“a condition that develops when the reflux of stomach contents into the oesophagus causes 
troublesome symptoms and/or complications”) is oversimplified in not accounting for 
functional GI syndromes (visceral hypersensitivity and central nervous system 
dysregulation).  
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Most patients with reflux symptoms (~65%) do not have erosive oesophagitis on upper 
endoscopy7 and form a heterogeneous group of patients. When subtyped using prolonged 
ambulatory oesophageal pH-metry, patients without erosive oesophgitis can be 
subcategorized as having one of three syndromes; (1) nonerosive reflux disease (NERD, 
~40%), wherein oesophageal acid exposure is quantifiably abnormal, (2) reflux 
hypersensitivity (~35%), wherein oesophageal acid exposure is quantifiably normal but 
symptoms are associated with reflux events, or (3) functional heartburn (~25%), wherein 
acid exposure is quantifiably normal and perceived symptoms are unrelated to reflux 
events.7 Thus, while the association between acidic gastro-oesophageal reflux, symptoms, 
and oesophagitis is sometimes beyond doubt, the expansive definition of GORD to include 
scenarios in which symptoms are only “potentially” attributable to acid or reflux is 
problematic for the clinician.1, 2 
Overutlisation of acid inhibition  
PPIs are effective for treating and maintaining healing of oesophagitis and their widespread 
use has made high-grade oesophagitis and oesophageal peptic strictures relatively 
uncommon. The link between GORD and oesophageal adenocarcinoma is likely mediated 
through inflammation (oesophagitis), metaplasia (Barrett’s oesophagus) and dysplasia. 
However, PPI use might not decrease cancer risk and, compared with healing osophagitis, 
they are less effective in resolving reflux symptoms. Persistent reflux symptoms are reported 
by up to 45% of PPI-treated patients in primary care and community studies.8 Nevertheless, 
PPI prescribing continues to increase globally and numerous studies report prescription of 
high-dose PPIs, without demonstrable improvement in symptoms, and perpetual PPI use in 
patients testing negative for gastro-oesophageal reflux. Furthermore, evidence suggests a 
systematic bias away from diagnosing functional GI disorder in favour of GORD.9  
Unease regarding the unnecessary risks and costs associated with overutilisation of PPIs 
has led to deprescribing initiatives. However, efforts to prevent PPI overuse are hindered by 
lack of guidance on alternative therapeutic approaches and, perhaps, lack of confidence 
among primary care clinicians to attribute uninvestigated symptoms to a functional condition. 
A detailed clinical history can help direct management  
Early identification of patients whose symptoms are less likely to respond to acid inhibition 
can change the narrative for patient counselling and support. To achieve this, we can take a 
page from irritable bowel syndrome (IBS) management; a functional condition wherein 
diagnostic and therapeutic approaches are based on a detailed history rather than routine 
testing to exclude alternative aetiologies.10 Similarly, endoscopy is not required in patients 
presenting with reflux symptoms, unless alarm symptoms are present (outlined in regional 
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guidelines, usually including dysphagia, food impaction, bleeding, unintentional weight loss). 
A thoughtful clinical history, taking a broad view of the patient’s health and symptoms, could 
identify clinical characteristics indicative of functional oesophageal syndromes, which often 
overlap other functional symptoms and psychological factors. Once the clinical history points 
toward altered perception, the most relevant modulating factors can be addressed to 
improve management (see Figure 1). 
Co-existing functional dyspepsia (nausea, early satiety, postprandial fullness, bloating), and 
IBS are observed more frequently in patients with functional heartburn than with 
oesophagitis or NERD, as are anxiety, depression, somatisation, and insomnia. 
Furthermore, a somatic symptom scale, i.e. the PHQ-12, can be useful to quickly identify 
signs of visceral hypersensitivity, such as backache, limb pain, palpitations or 
breathlessness.11 On the other hand, gender, age, central obesity and lifestyle factors are 
important risk factors for acid-related syndromes (Figure 1). Reflux oesophagitis is found 
significantly more commonly on endoscopy in men than women (15.9 ± 2.5% versus 6.1 ± 
1.6%, respectively; P < 0.0112) and, while older age is associated with more severe 
oesophagitis, functional heartburn has an inverse relationship with age.13 
Patient counselling  
A patient-centred approach is critical to elicit the motivation for consultation and the patient’s 
worries about their symptoms. Cultural and language differences might be obstacles and 
patients should be encouraged to describe symptoms in their own words rather than 
assigning them “best fit” medical terms. Anxiety about upper GI symptoms, rather than the 
frequency or severity of the symptoms themselves, often motivates consultation; 
reassurance is sometimes the most important aspect of management. Helping patients 
appreciate the balance between altered physiology and perception may promote 
engagement and acceptance of treatment advice. However, the concept of ‘acid reflux’ as a 
cause of upper GI symptoms is deep-rooted and there may be resistance to the suggestion 
that other factors, especially psychological ones, cause symptoms. It is important to 
introduce patients, at an early stage, to the concept of the mind-gut link and the possibility 
that their symptoms could be caused by heightened perception as well as gastro-
oesophageal reflux. This is especially important for patients with concomittant IBS, 
dyspepsia and other symptoms of functional disorder, because they are less likely to 
respond to PPI therapy.14,15 
Approaches to management 
Lifestyle factors 
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The advent of safe, readily available, and inexpensive acid inhibitors has largely sidelined 
modulation of lifestyle factors as a first-line approach to reflux management. In a UK study, 
less than a third (28%) of patients with heartburn or regurgitation were informed about 
lifestyle measures by their general practitioner.16 The situation is not helped by the lack of 
investigation of lifestyle interventions in controlled clinical studies. Nevertheless, it is sensible 
to provide lifestyle advice and help patients explore potential lifestyle changes. Central 
obesity is a strong risk factor for GORD and increases the risk of erosive oesophagitis, 
Barrett’s oesophagus, and oesophageal adenocarcinoma. Weight loss, even in non-obese 
patients, is proven to reduce oesophageal acid exposure and weight reduction has been 
shown to resolve refractory symptoms and reduce long-term PPI use.17 Similarly, smoking 
cessation has been shown to reduce reflux symptoms in normal weight individuals.18  
For nocturnal reflux symptoms, avoidance of late evening meals and head-of-the-bed 
elevation have demonstrated benefit. Evidence regarding specific dietary factors and reflux 
is generally sparse and conflicting. However, a recent prospective, primary care study 
showed that patients with reflux symptoms could identify at least one dietary trigger for their 
symptoms (e.g. spicy food, chocolate, tomato) and that eliminating this food reduced 
symptoms in the short-term.19 Furthermore, 45% of patients agreed to continue treatment 
with dietary intervention alone, rather than progress to pharmacological therapy.19 
PPI response does not equate to a diagnosis of GORD 
A short (4 to 8 week) course of PPI treatment is a pragmatic approach for patients 
presenting with reflux symptoms who are unsatisfied with lifestyle interventions and over-the-
counter therapies. However, PPI response does not equate to a diagnosis of GORD as it 
was demonstrated in 51% of primary care patients with upper GI symptoms who tested 
negative for GORD.20 Furthermore, functional heartburn has been diagnosed in about half of 
PPI non-responders and a fifth of PPI responders.21 Hence, PPI response is not a reliable 
diagnostic tool even though it can help guide management. 
PPI deprescribing 
Reflux symptoms may occur intermittently with varying intensity, often linked to dietary 
patterns or psychological stress. In such circumstances a short course of PPI treatment may 
suffice. Explaining the rationale for deprescribing can help patients accept the process. 
There are several deprescribing strategies, e.g., lowering the PPI dose from twice- to once-
daily, halving the dose, taking every second day, on-demand use, or stopping the PPI and 
using antacids, alginates, or an H2RA, as required. The strategy that is most acceptable to 
the patient is the one that should be used. Practical recommendations for when and how to 
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reduce or discontinue PPI are now available (Farrell et al. 201722) and a successful nurse-
led PPI deprescribing programme in UK primary care has also recently been reported.23 
 
Non-PPI options for persistent symptoms  
Efficacy in healing high-grade oesophagitis is the only aspect of reflux disease management 
in which escalating the potency of PPI therapy (higher dose, twice-daily dosing, or more 
potent drug) has a demonstrable therapeutic gain. In contrast, there is no therapeutic gain 
with increased PPI dosage in patients whose reflux symptoms are not responding to 
standard dose PPI.24 Poor adherence in terms of PPI dosing and timing (before meals) may 
be an issue, but evidence suggests that the refractoriness rate in nonerosive disease is still 
about 20% after dose optimisation.14 In a study of such patients, NERD, reflux 
hypersensitivity, and functional heartburn constituted 32%, 42%, and 26% of the total, 
respectively.14 Repetitive endoscopy should be avoided in such patients.3 Rather, they 
should be reassured and offered treatments to address the underlying pathophysiology, 
such as mucosal protection, neuromodulators, and behavioral therapy (Figure 1).25 
Treatments to coat the oesophagus and strengthen the mucosa barrier include alginate and 
hyaluronic acid plus chondroitin sulphate.26 These treatments may also help patients with 
breakthrough symptoms on PPI, or during PPI deprescribing when transient rebound 
symptoms may occur. Neuromodulator options include tricyclic antidepressants, selective 
serotonin receptor inhibitors, noradrenergic reuptake inhibitors, or gabapentenoids.3 These 
therapies may be beneficial for patients with functional heartburn and reflux hypersensitivity 
who often exhibit psychosocial distress and reduced health-related quality of life 
proportionate to their symptom severity (see Dickman et al. 201427 for details on specifics of 
drug selection and dosing). Alternative approaches such as cognitive behavioral therapy, 
advice on coping mechanisms, relaxation therapy, acupuncture, hypnotherapy and exercise 
are complementary approaches to neuromodulation in selected patients. At the other 
extreme, patients strongly suspected of having unresolved symptoms on PPI therapy that 
are related to uncontrolled reflux, should be referred for further investigation. They may 
require laparoscopic fundoplication to restore anti-reflux barrier function, which remains an 
effective treatment in appropriate patients.25 
 
Conclusion  
Reflux symptoms (heartburn, regurgitation) may be caused by altered physiology, altered 
perception, or both, but current treatment algorithms generally focus only on altered 
physiology. Although a short course of a PPI remains a mainstay of management, it should 
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be used in conjunction with a good clinical history to help direct long-term management, 
including deprescribing and non-pharmacological interventions. There is no demonstrable 
therapeutic gain to dose escalation of PPIs in patients with suspected functional syndromes 
whose reflux symptoms are not responding to a standard dose. These patients should 
instead be managed with a combination of non-PPI therapeutic approaches such as lifestyle 
modifications, neuromodulators, mucosal protection, reassurance and psychological support. 
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Figure 1. Tailoring reflux symptom management to the suspected underlying 
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